Dr. Gregory P. Kalemkerian

Dr. Gregory P. Kalemkerian M.D.

Dr. Gregory P. Kalemkerian is an Associate Professor for Internal Medicine at the University of Michigan Cancer Center in Ann Arbor.

(734) 615-4762
N/A
1500 E Medical Center Dr, Ann Arbor, MI 48109

Dr. Gregory P. Kalemkerian is an Associate Professor for Internal Medicine at the University of Michigan Cancer Center in Ann Arbor. He is also the Co-Director of the Thoracic Oncology Program at the Department of Internal Medicine which is part of the University of Michigan Health System. His clinical interests include malignant mesothelioma care and treatment, lung cancer, thoracic cancer, and the epidemiology of lung cancer and thymoma. His research interest is in experimental therapeutics. Within the Department of Internal Medicine, Dr. Kalemkerian’s specialties are in hematology and oncology, as well as thoracic oncology.

Education and Training

Dr. Kalemkerian received his medical doctorate in 1985 from Northwestern University located in Illinois which is also where he completed his residency. Dr. Kalemkerian’s fellowship in medical oncology was conducted in 1992 at Johns Hopkins University. Additionally, Dr. Kalemkerian achieved Board Certification in both Internal Medicine and Medical Oncology, and was recertified in 2001 for Medical Oncology.

Dr. Kalemerian is an active member of several organizations, groups, and societies including the Radiation Therapy Oncology Group (DTOG), Southwest Oncology Group (SOG), and the American Society of Clinical Oncology (ASCO).

Research and Publications

Dr. Kalemkerian is published in various peer-reviewed journals which are mainly devoted to small cell lung cancer development and treatment. The Thoracic Oncology Program, of which Dr. Kalemerian is Co-Director, focuses on treating patients with various types of lung cancer by integrating multiple modalities such as surgery, chemotherapy, and radiation therapy. The program has also developed and participated in numerous clinical trials for patients with all stages of small cell and non-small cell lung cancer to evaluate novel therapeutic strategies using cutting-edge chemotherapy agents and radiotherapy techniques.

Reference: